Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Memory | 2 | 2021 | 199 | 1.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2025 | 449 | 1.190 |
Why?
|
| Dendritic Cells | 7 | 2025 | 448 | 1.120 |
Why?
|
| Immunotherapy | 3 | 2019 | 748 | 0.740 |
Why?
|
| Dog Diseases | 2 | 2020 | 59 | 0.740 |
Why?
|
| Receptors, IgG | 1 | 2021 | 62 | 0.680 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2021 | 520 | 0.660 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 46 | 0.580 |
Why?
|
| Doxorubicin | 1 | 2019 | 303 | 0.540 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 188 | 0.530 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2017 | 53 | 0.530 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 165 | 0.490 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 1018 | 0.420 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2013 | 62 | 0.380 |
Why?
|
| Vaccines | 1 | 2017 | 381 | 0.380 |
Why?
|
| Influenza A virus | 1 | 2013 | 152 | 0.370 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 688 | 0.320 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 1759 | 0.310 |
Why?
|
| CTLA-4 Antigen | 2 | 2020 | 66 | 0.290 |
Why?
|
| Th1 Cells | 3 | 2025 | 159 | 0.280 |
Why?
|
| Amino Acyl-tRNA Synthetases | 2 | 2024 | 26 | 0.260 |
Why?
|
| Animals | 13 | 2024 | 34995 | 0.230 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2025 | 6 | 0.230 |
Why?
|
| Mice, Inbred BALB C | 3 | 2020 | 1052 | 0.230 |
Why?
|
| Cytokines | 2 | 2025 | 1368 | 0.230 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 4695 | 0.200 |
Why?
|
| Dogs | 2 | 2020 | 655 | 0.180 |
Why?
|
| Cannabidiol | 1 | 2020 | 21 | 0.170 |
Why?
|
| Immune System | 1 | 2020 | 97 | 0.160 |
Why?
|
| Arthralgia | 1 | 2020 | 68 | 0.160 |
Why?
|
| Homeostasis | 1 | 2024 | 730 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 210 | 0.160 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 84 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 356 | 0.160 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2020 | 105 | 0.160 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 204 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 2020 | 103 | 0.150 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 102 | 0.150 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 351 | 0.140 |
Why?
|
| Immunophenotyping | 1 | 2019 | 344 | 0.140 |
Why?
|
| Mice | 6 | 2024 | 18572 | 0.130 |
Why?
|
| Antigens, Protozoan | 1 | 2017 | 79 | 0.130 |
Why?
|
| Drug Carriers | 1 | 2017 | 119 | 0.130 |
Why?
|
| Transduction, Genetic | 1 | 2017 | 294 | 0.130 |
Why?
|
| Bystander Effect | 1 | 2016 | 6 | 0.130 |
Why?
|
| Peptides | 1 | 2020 | 847 | 0.130 |
Why?
|
| B7 Antigens | 1 | 2016 | 14 | 0.120 |
Why?
|
| Vaccines, Synthetic | 1 | 2017 | 322 | 0.120 |
Why?
|
| Cytosol | 1 | 2015 | 144 | 0.120 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2015 | 51 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1297 | 0.110 |
Why?
|
| Interferon-gamma | 1 | 2017 | 539 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 95 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2017 | 596 | 0.110 |
Why?
|
| Immunomodulation | 2 | 2024 | 78 | 0.110 |
Why?
|
| Neoplasms | 3 | 2025 | 2946 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2017 | 927 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2017 | 1570 | 0.100 |
Why?
|
| Vaccination | 1 | 2019 | 1017 | 0.100 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2013 | 11 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2019 | 3062 | 0.100 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2013 | 62 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2015 | 414 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 701 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 605 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 1357 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 4767 | 0.060 |
Why?
|
| Humans | 9 | 2025 | 132348 | 0.060 |
Why?
|
| Open Reading Frames | 1 | 2006 | 219 | 0.060 |
Why?
|
| Genome, Insect | 1 | 2006 | 109 | 0.060 |
Why?
|
| Multigene Family | 1 | 2006 | 305 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2006 | 333 | 0.060 |
Why?
|
| Immunoassay | 1 | 2025 | 135 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2025 | 142 | 0.050 |
Why?
|
| Female | 3 | 2024 | 70795 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2025 | 436 | 0.050 |
Why?
|
| Drosophila | 1 | 2006 | 822 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2017 | 13017 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2006 | 768 | 0.040 |
Why?
|
| Cannabis | 1 | 2020 | 50 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 2145 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2024 | 550 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 273 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 3023 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 2064 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3698 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1648 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1683 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2016 | 50 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 2673 | 0.030 |
Why?
|
| Peptide Elongation Factors | 1 | 2015 | 13 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 60 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 5010 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 399 | 0.030 |
Why?
|
| Monocytes | 1 | 2016 | 345 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 691 | 0.030 |
Why?
|
| Male | 1 | 2019 | 65061 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 493 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2446 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 891 | 0.020 |
Why?
|
| Macrophages | 1 | 2015 | 693 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 1285 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 4725 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2512 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 1526 | 0.020 |
Why?
|
| Species Specificity | 1 | 2006 | 544 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 1426 | 0.010 |
Why?
|